



## Graham Blakey

Clinical pharmacology and pharmacokinetics consultant

Location: Nottingham, United Kingdom

Industry: Pharmaceutical Development

## Career Summary

2007 – present

GBPK Consulting Ltd

Director

2002 - 2007

AstraZeneca R&D Charnwood, Loughborough

Principal Scientist,

Head of Clinical Pharmacokinetics

1995 - 2002

AstraZeneca R&D Charnwood, Loughborough

Senior Clinical Pharmacokineticist

1991 - 1995

Department of Pharmacy,

University of Manchester

Post-Graduate (PhD)

1990 - 1991

Department of Pharmacy,

University of Strathclyde

Research Assistant

1989 - 1990

Department of Medicine and Therapeutics,

Stobhill Hospital, Glasgow

Post-Graduate (MSc)

1987 - 1989

Teaching hospitals,

Newcastle upon Tyne

Pharmacist

1986 - 1987

Hope Hospital, Salford

Pre-registration Pharmacy student

1983 - 1986

School of Pharmacy,

Leicester Polytechnic

Undergraduate

## Bibliography

Whitehead J, Zhou Y, Stevens J, Blakey G, Price J, Leadbetter J. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. *Statistics in Medicine* 25 (1) 37-53 (2006)

Whitehead, J, Zhou Y, Stevens J, Blakey G. An evaluation of a Bayesian method of dose-escalation based on bivariate binary responses. *Journal Biopharmaceutical Statistics* 14 (4) 969-83 (2004)

Blakey GE, Lockton JA, Perrett J, et al. Pharmacokinetic and pharmacodynamic assessment of a 5 probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. *Br. J. Clin. Pharmacol.* 57 162-9 (2004)

Besag FMC, Newton ER, Blakey GE et al. The safety, tolerability and pharmacokinetics of remacemide in children. *Paediatric Neurology* 24 352-6 (2001)

Hooper WD, Eadie MJ, Blakey GE et al. Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males. *Br. J. Clin. Pharmacol* 51 249-255 (2001).

Blakey GE, Ballard P, Leahy DE, Rowland M. Development of an assay for the extraction and quantification of nine 5-n-alkyl-5-ethyl barbituric acids in various rat tissues. *J. Pharm. Biomed. Anal.* 18 927-938 (1999)

Blakey GE, Nestorov IA, Arundel PA, Aarons LJ, Rowland M. Quantitative structure-pharmacokinetics relationships. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a series of barbiturates in the rat. *J. Pharmacokin. Biopharm.* 25 277- 312 (1997)

Ballard P, Rowland M, Leahy D, Blakey G. Analytical approaches adopted for determining a congeneric series of 5-alkyl-5-ethyl barbituric acid derivatives in rat tissues. *Methodol. Surv. Bioanal. Drugs* 23 229-236 (1994)